Xencor, Inc. Overview
Pro stress-test →Xencor is a clinical-stage biopharmaceutical company focused on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. The company is built on superior Fc domain expertise and is an industry leader in the development of bispecific antibodies.
Strategic Profile
Pro stress-test →Xencor generates revenue primarily through collaboration agreements, product licensing, and technology licensing, partnering with major pharmaceutical companies to advance its biotherapeutic products. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and multiple XmAb medicines are marketed by partners. The company's lead oncology drug candidate is XmAb819, a novel first-in-class T-cell engager that could offer a much-needed new therapeutic modality for patients with advanced clear cell renal cell carcinoma (ccRCC), with plans to present dose-expansion data during a medical meeting in the second half of 2026 and initiate a pivotal study during 2027.
Competitive Landscape
Pro stress-test →Xencor competes within the bispecific antibody and engineered therapeutics space against established players and specialized biotech firms. Market comparables include Arcus Biosciences ($2.65B market cap), Protagonist Therapeutics ($5.23B), Relay Therapeutics ($1.38B), and MacroGenics ($109M). Xencor's differentiation centers on its Fc domain expertise and XmAb platform superior to traditional antibody approaches.
Industry Context
Xencor, Inc. operates in Biotechnology - Antibody Therapeutics & Biopharmaceuticals.
Key facts
Founded: 1997 · Headquarters: Pasadena, California · Employees: 250 · Revenue: $75M · Market cap: $1.0B